Company intelligence / Profile preview

Treeway

Ownership: Private
Development stage: Phase 3

Overview

Treeway's lead product TW001 (FNP122) has entered Phase 3 clinical trials for ALS treatment. The company has also shown promising results in Phase 1 trials for TW001. Their Alzheimer's disease program (TW101) is also in development.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small molecule drugsBiological products
Industry: Biotech

Drug pipeline

1 asset

TW002

Preclinical

Partnerships

Ferrer (for FNP122/TW001)3D-PharmXchange

Beyond the preview

Go deeper on Treeway.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treeway.

Explore the full profile